CA2124217A1 - Inactivation de produits cytotoxiques - Google Patents

Inactivation de produits cytotoxiques

Info

Publication number
CA2124217A1
CA2124217A1 CA002124217A CA2124217A CA2124217A1 CA 2124217 A1 CA2124217 A1 CA 2124217A1 CA 002124217 A CA002124217 A CA 002124217A CA 2124217 A CA2124217 A CA 2124217A CA 2124217 A1 CA2124217 A1 CA 2124217A1
Authority
CA
Canada
Prior art keywords
component
drug
cytotoxic
inactivating
host
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002124217A
Other languages
English (en)
Inventor
Kenneth D. Bagshawe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzacta R&D Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2124217A1 publication Critical patent/CA2124217A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/67—Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
CA002124217A 1992-01-09 1993-01-11 Inactivation de produits cytotoxiques Abandoned CA2124217A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9200415.9 1992-01-09
GB929200415A GB9200415D0 (en) 1992-01-09 1992-01-09 Inactivation of cytotoxic drugs
GB929204104A GB9204104D0 (en) 1992-01-09 1992-02-26 Inactivation of cytotoxic drugs
GB9204104.5 1992-02-26

Publications (1)

Publication Number Publication Date
CA2124217A1 true CA2124217A1 (fr) 1993-07-22

Family

ID=26300132

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002124217A Abandoned CA2124217A1 (fr) 1992-01-09 1993-01-11 Inactivation de produits cytotoxiques

Country Status (5)

Country Link
EP (1) EP0620742A1 (fr)
JP (1) JPH07506339A (fr)
CA (1) CA2124217A1 (fr)
GB (3) GB9200415D0 (fr)
WO (1) WO1993013806A1 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5264220A (en) * 1991-11-12 1993-11-23 Long David M Jr Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
ES2276519T3 (es) * 1998-05-22 2007-06-16 Abbott Laboratories Un medicamento antiangiogenico para el tratamiento del cancer, de la artritis y de la retinopatia.
CO5170498A1 (es) * 1999-05-28 2002-06-27 Abbott Lab Biaril sulfonamidas son utiles como inhibidores de proliferacion celular
FR2883873B1 (fr) 2005-03-31 2009-07-10 Pharmamens Sarl Inhibiteurs d'age
US7732309B2 (en) * 2006-12-08 2010-06-08 Applied Materials, Inc. Plasma immersed ion implantation process
DK2603528T3 (en) 2010-08-10 2016-11-28 Glycotope Gmbh FAB-glycosylated ANTIBODIES
DK3794042T3 (da) 2018-05-18 2024-04-15 Daiichi Sankyo Co Ltd Anti-muc1-exatecet-antistof-lægemiddelkonjugat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
US4859449A (en) * 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
GB8809616D0 (en) * 1988-04-22 1988-05-25 Cancer Res Campaign Tech Further improvements relating to drug delivery systems
US4905949A (en) * 1989-02-13 1990-03-06 Cosgrove James H Device for releasably supporting a plurality of objects
WO1990010460A1 (fr) * 1989-03-13 1990-09-20 Kenneth Naoyuki Matsumura Procede de reduction des effets secondaires d'un medicament
WO1991009134A1 (fr) * 1989-12-15 1991-06-27 Takeda Chemical Industries, Ltd. Anticorps biospecifique des cellules cancereuses et enzyme presentant des caracteristiques d'activation promedicamenteuse
CA2062582C (fr) * 1991-03-27 1996-03-26 Tse-Wen Chang Methodes et substances pour recruter des agents therapeutiques a des tissus solides

Also Published As

Publication number Publication date
GB2276624B (en) 1995-10-25
GB2276624A (en) 1994-10-05
EP0620742A1 (fr) 1994-10-26
WO1993013806A1 (fr) 1993-07-22
GB9410237D0 (en) 1994-07-27
JPH07506339A (ja) 1995-07-13
GB9200415D0 (en) 1992-02-26
GB9204104D0 (en) 1992-04-08

Similar Documents

Publication Publication Date Title
US6299876B1 (en) Cytotoxic drug therapy
Melton et al. Antibody-enzyme conjugates for cancer therapy
Bagshawe Antibody directed enzymes revive anti-cancer prodrugs concept.
EP0408546B1 (fr) Amelioration apportees a des systemes d'administration de medicaments
US5683694A (en) Method for the treatment of tumors with conjugated antibody A5B7 and a prodrug
EP0633029B1 (fr) Amélioration aux systèmes de déliverance de médicaments
EP0031999B1 (fr) Protéine hybride antitumeur et procédé pour sa préparation
Ghose et al. Antibody-linked cytotoxic agents in the treatment of cancer: current status and future prospects
Senter et al. Generation of 5-fluorouracil from 5-fluorocytosine by monoclonal antibody-cytosine deaminase conjugates
EP0306943B1 (fr) Immunoconjugués liés par liaisons thioéthers ayant une toxicité réduite et une sélectivité augmentée
EP1027073A2 (fr) Effets renforces pour therapeutique associee a l'haptene
JP2001512438A (ja) αガラクトシルエピトープで標識された抗体による免疫応答の刺激
US5716990A (en) Drug delivery systems
CA2124217A1 (fr) Inactivation de produits cytotoxiques
Bagshawe Antibody-directed enzyme prodrug therapy (ADEPT)
EP0918545B1 (fr) Therapie tumorale
US5151266A (en) Use of anionic detergents with conjugates of monoclonal or polyclonal antibodies
CA2239203A1 (fr) Traitement medicamenteux
CA2155953A1 (fr) Conjugues de proteines; compositions qui en renferment et leur utilisation comme medicaments
CA1341383C (fr) Ameliorations portant sur l'administration d'un medicament au site vise
US20020127229A1 (en) Tumour therapy
Hellstrom et al. Generation of 5-Fluorouracil from 5-Fluorocytosine by Monoclonal Antibody-Cytosine Deaminase Conjugates

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead